Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of CD22-directed CAR-T cells (SHB-04-CD22) in relapsed or refractory CD22-positive B-cell malignancies
MOH_2026-01-15_015604Phase 2Not yet recruiting
- Sponsor
- ד"ר ג'ונתן היינס אזנשטיין
- Start
- Jan 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SHB-04-CD22 in B-cell malignancy, acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL) and 1 more, sponsored by ד"ר ג'ונתן היינס אזנשטיין. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
SHB-04-CD22
03
Conditions
B-cell malignancyacute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on MOH_2026-01-15_015604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-01-15_015604.